Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
Ida H Hiemstra's research works Genmab, Copenhagen and other places
PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect
Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
Ida H Hiemstra's research works Genmab, Copenhagen and other places
CD38 treatment and PD-1/PD-L1. Nivolumab significantly reduced the
eBioMedicine, Vol 93, July 2023
de
por adulto (o preço varia de acordo com o tamanho do grupo)
